Dow Agro posts record fourth quarter profit
The Indianapolis-based unit of Dow Chemical Co. saw earnings grow to $142 million, a fourth-quarter record and double the $72 million reported for the 2010 period.
Life Science & Biotech
Articles
Lilly’s quarterly profit tumbles, but tops Wall Street estimates
Patent expirations on Gemzar and Zyprexa contributed to the 27-percent earnings decline, but CEO John Lechleiter touted better-than-expected sales of other products.
Purdue hopes center simplifies commercialization
Purdue University’s new Innovation and Commercialization Center is supposed to be a one-stop shop for professors to get help developing their research into products and for outside investors to find out what research is taking place there.
Eli Lilly unit plans to buy feed-enzyme maker
Drugmaker Eli Lilly and Co.'s Elanco animal health division plans to buy a privately held maker of feed-enzyme products that improve poultry, egg and meat production.
Indianapolis-area mergers and acquisitions in 2011
A number of acquisitions last year disclosed no sale price. In the Indianapolis area, those deals ranged from MacAllister Machinery’s purchase of a Caterpillar dealership in Michigan to Herff Jones’ acquisition of a Memphis, Tenn.-headquartered maker of cheerleading uniforms.
City set to cancel tax abatement for medical device firm
Polymer Technology Systems said in 2007 that it would make a $3 million investment at its operation on Zionsville Road and create 110 jobs.
At long last, Roche wins approval of Nano
The OK for a new blood glucose monitor comes more than two years after FDA officials declined to approve a previous version of the Nano, which in rare cases generated inflated blood sugar readings because it did not distinguish properly between the sugars glucose and maltose.
Indiana’s medical device workforce will need skills upgrade
A new report by BioCrossroads says 53 percent of the 20,000 jobs in Indiana’s medical-device sector require no more than a high school education.
National life sciences law firm opens office here
New York-based Epstein Becker Green already has clients here, including Biomet and Roche Diagnostics.
Endocyte stays course despite being battered by investors
After spending most of 2011 as a Wall Street darling, the year ended ugly for Endocyte Inc. But CEO Ron Ellis thinks the West Lafayette-based drug developer is in better position than ever.
Filing: Roche considered leaving Indy
It’s hard to believe now, but as recently as two years ago, Indianapolis was close to losing its 15th-largest employer. Roche Diagnostics Corp. was looking seriously at moving its 2,900-employee North American headquarters out of Indianapolis.
Ex-Dow Agro scientist receives seven years for economic espionage
Kexue Huang was sentenced after pleading guilty in October to sending Dow AgroSciences trade secrets to China and Germany.
Ex-Dow Agro scientist set to be sentenced in espionage case
Federal prosecutors are recommending that Kexue Huang be sentenced to 87 months in prison for sending trade secrets worth millions to China and Germany.
SEC accuses Positron CEO of misleading investors
Regulators allege CEO Patrick G. Rooney diverted millions of dollars from a hedge fund into the struggling Fishers company without investors’ knowledge.
Purdue courts Silicon Valley partnerships
The office, at NASA Ames Research Center, in Mountain View, Calif., aims to commercialize Purdue-developed technology through partnerships with private industry.
JONES: Patent reform is mixed bag for life sciences companies
For Indiana’s life sciences sector, the change both raises hopes and creates challenges for continued growth.
Cancer-drug firm Endocyte to build commercial team in Indianapolis
Endocyte employs 12 people in Indianapolis and plans to add three or four more commercial executives there over the next year and a half as it anticipates approval of its ovarian cancer medication in Europe.
Drug shortages hit Lilly, Endocyte
The nation’s shortage of certain drugs is threatening to affect research trials being conducted by Eli Lilly and Co. and Endocyte Inc.
Insurer Humana’s quarterly profit climbs 13 percent
Humana Inc. raised its 2011 earnings forecast, following the lead set by other big insurers, including competitor WellPoint Inc.
Ortho firms pull back on doc payments
The number of payments in excess of $1 million didn’t change substantially from year to year, but orthopedic companies sharply cut their fees to surgeons who received the smallest amounts.